Top 5 Takeaways Pronounced Disparities: From April to July 2022, Paxlovid treatment among COVID-19 patients aged ≥20 years was significantly lower for Black (35.8% less) and Hispanic (29.9% less) patients
Tag: COVID
Top 5 Takeaways Bivalent mRNA COVID-19 Vaccine Effectiveness: The bivalent mRNA COVID-19 vaccine was found to be 47% effective in preventing thromboembolic events in immunocompetent persons aged ≥65 years and
Top 5 Takeaways: Safety Profile Similar to Monovalent Boosters: Early safety findings for bivalent COVID-19 mRNA booster doses in persons aged ≥12 years are consistent with those reported for monovalent
Top 5 Takeaways Bivalent Booster Recommendation: In fall 2022, the CDC recommended a bivalent mRNA COVID-19 vaccine booster dose for individuals aged 5 years and older, to be administered at
Top 5 Takeaways Increased Hospitalization Rates: During the Omicron variant-predominant periods, hospitalization rates among infants aged <6 months increased compared to the Delta variant period, but severe disease indicators among
Top 5 Takeaways Perception vs Reality: Half of the surveyed adults in Michigan and Illinois who had recent SARS-CoV-2 infections perceived local COVID-19 transmission as low or moderate, despite high
Top 5 Takeaways Low Vaccination Rates Among Young Children: As of July 2022, only 4% of children aged 6 months–4 years had received at least one dose of the COVID-19
Top 5 Takeaways 1. 41.6% of adults had antibodies indicating past SARS-CoV-2 infection during August 2021–May 2022, with 43.7% potentially asymptomatic. 2. Seropositivity without vaccination was more common among younger
Top 5 Takeaways Paxlovid, an outpatient antiviral medication, is linked to a 51% reduction in hospitalization rates for COVID-19 among U.S. adults when prescribed within 5 days of diagnosis. This
Top 5 Takeaways Bivalent Boosters’ Effectiveness: The study reveals that bivalent mRNA COVID-19 boosters offer significant additional protection against symptomatic SARS-CoV-2 infection, especially for those who had 2 to 4